L1CAM Is Not a Reliable Diagnostic Biomarker for Distinguishing Supratentorial Ependymomas, ZFTA Fusion-Positive From Other Central Nervous System Tumors

J Neuropathol Exp Neurol. 2022 Jan 21;81(1):82-85. doi: 10.1093/jnen/nlab105.

Authors

Oumaima Aboubakr¹, Alice Metais¹, Charlotte Berthaud¹, Priscille Gigant¹, Leïla Mehdi¹, Noémie Pucelle¹, Joëlle Lacombe¹, Lauren Hasty¹, Fabrice Chrétien^{1

2}, Emmanuèle Lechapt^{1

2}, Pascale Varlet^{1

2

3}, Arnault Tauziède-Espariat^{1

2

3}

Affiliations

¹ Department of Neuropathology, GHU Paris-Psychiatry and Neurosciences, Sainte-Anne Hospital, Paris, France.
² Université de Paris, Paris, France.
³ Institute of Psychiatry and Neurosciences de Paris (IPNP), UMR S1266, INSERM, IMA-BRAIN, Paris, France.

PMID: 35062030
DOI: 10.1093/jnen/nlab105

No abstract available

Publication types

Letter

MeSH terms

Biomarkers, Tumor / analysis*
Child
Diagnosis, Differential
Ependymoma / diagnosis*
Ependymoma / genetics
Female
Humans
Male
Neural Cell Adhesion Molecule L1 / analysis
Neural Cell Adhesion Molecule L1 / biosynthesis*
Oncogene Proteins, Fusion / genetics
Proteins / genetics*
Sensitivity and Specificity
Supratentorial Neoplasms / diagnosis*
Supratentorial Neoplasms / genetics

Substances

Biomarkers, Tumor
C11orf95 protein, human
L1CAM protein, human
Neural Cell Adhesion Molecule L1
Oncogene Proteins, Fusion
Proteins

Supplementary concepts

Familial ependymoma